Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus (ASTRIDE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00787605
Recruitment Status : Completed
First Posted : November 7, 2008
Results First Posted : May 23, 2011
Last Update Posted : October 27, 2016
Information provided by:

November 5, 2008
November 7, 2008
December 20, 2010
May 23, 2011
October 27, 2016
November 2008
January 2010   (Final data collection date for primary outcome measure)
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) [ Time Frame: Baseline and Week 8 ]
Change in msSBP after 8 weeks of treatment [ Time Frame: 8 weeks ]
Complete list of historical versions of study NCT00787605 on Archive Site
  • Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) [ Time Frame: Baseline and Week 8 ]
  • Percentage of Responders [ Time Frame: Week 8 ]
    Response defined by mean sitting Systolic Blood Pressure < 130 mm Hg or a reduction of mean sitting Systolic Blood Pressure >= 20 mm Hg from baseline
  • Percentage of Patients Achieving Blood Pressure Control [ Time Frame: after 8 weeks of treatment ]
    Blood pressure control is defined as patient achieving a target Blood Pressure of mean sitting Systolic BloodPressure / mean sitting Diastolic Blood Pressure < 130/80 mmHg.
  • Biomarker Measurements [ Time Frame: Baseline and Week 8 ]
    Geometric mean of the post to baseline ratio in biomarkers of plasma renin activity (ng/ml/h), plasma renin concentration (ng/L), and cystatin C (mg/L)
  • Evaluate the Safety and Tolerability [ Time Frame: after 8 weeks of treatment ]
    Percentage of patients with Adverse Event and percentage of patients with edema
  • Evaluate the safety and tolerability of aliskiren HCTZ versus amlodipine [ Time Frame: 8 weeks ]
  • Change from baseline in mean sitting diastolic BP after 8 weeks of treatment [ Time Frame: 8 weeks ]
  • Percent of responders with aliskiren HCTZ vs amlodipine after 8 weeks of treatment [ Time Frame: 8 weeks ]
  • Proportion of patients achieving BP control after 8 weeks of treatment [ Time Frame: 8 weeks ]
  • Change from baseline in biomarkers measurements [ Time Frame: 8 weeks ]
Not Provided
Not Provided
Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
An 8-week Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus
The purpose of the study is to evaluate the blood pressure lowering effect and safety of aliskiren in combination with Hydrochlorothiazide (HCTZ) given to diabetic patients with stage 2 systolic hypertension (mean sitting systolic blood pressure (msSBP) ≥ 160 mm Hg and < 200 mm Hg).
Not Provided
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
  • Hypertension
  • Diabetes Mellitus
  • Drug: Amlodipine
    Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
  • Drug: Hydrochlorothiazide (HCTZ)
    Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
  • Drug: Aliskiren
    Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
  • Active Comparator: Amlodipine
    Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
    Intervention: Drug: Amlodipine
  • Experimental: Aliskiren / HCTZ
    Aliskiren / HCTZ 150/12.5 mg for 1 week followed by 300/25 mg for 7 weeks
    • Drug: Hydrochlorothiazide (HCTZ)
    • Drug: Aliskiren
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
January 2010
January 2010   (Final data collection date for primary outcome measure)

Inclusion criteria:

  1. Male or female outpatients ≥ 18 years old.
  2. Patients with a diagnosis of stage 2 hypertension (defined as an office cuff msSBP ≥ 160 mmHg and < 200 mmHg) at Visit 5 (randomization).
  3. Patients with diabetes mellitus (Type 2) with an HbA1c at visit 1 ≤ 9.0 % and currently on stable anti-diabetic regimen or stable diet and exercise for at least 4 weeks prior to visit 1.
  4. Patients who are eligible and able to participate in the study, and who are willing to give written informed consent before any assessment is performed.

Exclusion criteria:

  1. Office blood pressure measured by cuff (msSBP ≥ 200 mmHg or msDBP ≥ 110 mmHg) at Visits 1-5.
  2. History or evidence of secondary hypertension of any etiology (e.g., uncorrected renal artery stenosis, pheochromocytoma).
  3. History of hypertensive encephalopathy or heart failure (NYHA Class II-IV).
  4. Cerebrovascular accident, transient ischemic cerebral attack (TIA), coronary bypass surgery, myocardial infarction or any percutaneous coronary intervention (PCI) within 1 year prior to Visit 1.
  5. Serum sodium less than the lower limit of normal, serum potassium < 3.5 mEq/L (corresponding to 3.5 mmol/L) or ≥ 5.3 mEq/L (corresponding to 5.3 mmol/L), or dehydration at Visit 1.
  6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL).
  7. Use of other investigational drugs within 30 days of enrollment.
  8. History of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (thiazide diuretics, renin inhibitors, calcium channel blockers, or dihydropyridine like calcium channel blockers) as the study drugs.
  9. History of gouty arthritis.
  10. Long QT syndrome or QTc > 450 msec for males and > 470 msec for females at screening.
  11. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
  12. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS they are using two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method.

    • Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent. Reliable contraception should be maintained throughout the study and for 7 days after study drug discontinuation.
    • Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL (and estradiol< 20 pg/mL) or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
  13. Known Keith-Wagener grade III or IV hypertensive retinopathy.
  14. Current angina pectoris requiring pharmacological therapy (except sublingual nitroglycerin).
  15. Second or third degree heart block without a pacemaker.
  16. Atrial fibrillation or atrial flutter at Visit 1, or potentially life-threatening or any symptomatic arrhythmia during the 12 months prior to Visit 1.
  17. Clinically significant valvular heart disease.
  18. History of angioedema during use of an ACE inhibitor.
  19. History or evidence of drug or alcohol abuse within the last 12 months.
  20. Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study.
  21. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:

    • History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection.
    • History of active inflammatory bowel disease during the 12 months prior to Visit 1.
    • Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal bleeding during the 3 months prior to Visit 1.
    • Any history of pancreatic injury, pancreatitis, or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase during the 12 months prior to Visit 1.
    • Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3 x ULN at Visit 1, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt.
    • Evidence of renal impairment as determined by any one of the following: serum creatinine > 1.5 x ULN at Visit 1, a history of dialysis, or a history of nephrotic syndrome.
    • Current treatment with cholestyramine or colestipol resins
  22. History of noncompliance to medical regimes or unwillingness to comply with the study protocol.
  23. Any condition that in the opinion of the investigator would confound the evaluation and interpretation of efficacy and/or safety data.
  24. Persons directly involved in the execution of this protocol.
  25. Known contraindications to the study drugs.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
External Affairs, Novartis
Not Provided
Study Chair: Novartis Novartis
May 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP